Press Room

CUHK and HKSTP partner to establish a world-class GMP facility to drive cell therapy development in Hong Kong


29 Oct 2020


Mr. Albert Wong, CEO of HKSTP (left, 1st row) and Professor Wai-yee Chan, Pro-Vice-Chancellor and Vice-President of CUHK (right, 1st row), signed a collaboration agreement to establish Hong Kong’s world-class Good Manufacturing Practice (GMP) facility. Attending guests included:  (2nd row from left to right) Dr. Sunny Chai, Chairman, HKSTP Ms. Annie Choi, Permanent Secretary for Innovation and Technology Mr. Alfred Sit, Secretary for Innovation and Technology Ms. Rebecca Pun, Commissioner for Innovation and Technology Prof. Rocky Tuan, Vice-Chancellor and President, CUHK

Mr. Albert Wong, CEO of HKSTP (left, 1st row) and Professor Wai-yee Chan, Pro-Vice-Chancellor and Vice-President of CUHK (right, 1st row), signed a collaboration agreement to establish Hong Kong’s world-class Good Manufacturing Practice (GMP) facility. Attending guests included:

(2nd row from left to right)

  • Dr. Sunny Chai, Chairman, HKSTP
  • Ms. Annie Choi, Permanent Secretary for Innovation and Technology
  • Mr. Alfred Sit, Secretary for Innovation and Technology
  • Ms. Rebecca Pun, Commissioner for Innovation and Technology
  • Prof. Rocky Tuan, Vice-Chancellor and President, CUHK

(Hong Kong, 29 October 2020) - The Chinese University of Hong Kong (CUHK) and Hong Kong Science and Technology Parks Corporation (HKSTP), announce their partnership to build a world-class Good Manufacturing Practice (GMP) facility in Hong Kong to accelerate the development of life-saving cancer therapies, regenerative medicine, and related biomedical technologies.

As the city’s biomedical sector undergoes accelerated growth, there is an increasing demand for supporting facilities that comply with PIC/S GMP standards, required for the development and manufacture of Advanced Therapy Products (ATPs). These products, including those for stem cell therapy, gene therapy and immunotherapy, can potentially provide new and life-saving treatments for diseases with limited or no treatment options including cancers, cardiovascular and neurological diseases.

To facilitate the development of this emerging class of medicines, and safeguard public health, the HKSAR passed the Pharmacy and Poisons (Amendment) 2020 Ordinance (CAP. 138), which provides that the requirements for pharmaceutical products under this ordinance shall also apply to ATPs. All manufacturers of ATPs will need to obtain a licence to fully comply with the PIC/S GMP standards when producing such products for both clinical trials and the commercial markets.

In response, CUHK and HKSTP are joining forces to establish a GMP facility for cell therapy, as part of their strategic collaboration to accelerate translational medicine development.

Albert Wong, CEO of HKSTP, said, “The partnership with CUHK addresses a great public health challenge. Building this world-class GMP facility will bridge the gap between Hong Kong’s thriving biomedical technology development with the international healthcare sector. It also brings top researchers from academia and promising start-ups together, to advance Hong Kong’s international position in biomedical technology.”

Professor Wai-yee Chan, Pro-Vice-Chancellor and Vice-President of CUHK, said, “CUHK has always been committed to promoting research development in Hong Kong. The University is very pleased to be collaborating with HKSTP in establishing a world-standard GMP facility. This is good news for both CUHK and the industry as this facility provides an ideal environment for researchers with expertise in cell therapy and regenerative medicine in Hong Kong to implement clinical trials, as well as receiving support in research and professional training. I strongly believe that it will bring new breakthroughs in cell therapy in the future and will benefit more cancer patients.”

The facility aims to accelerate the development of ATPs from bench-to-bedside, while stimulate the testing and commercialisation process. Clinical trials in cell-based cancer therapies such as chimeric antigen receptor T-cell (CAR-T) and stem cell-based regenerative therapies will be the initial focus of the facility. As part of the launch, relevant scientists and operators will receive training to operate, audit and regulate both the facility, and the products manufactured.

The sophisticated GMP facility will be built inside the Hong Kong Institute of Biotechnology (HKIB), a CUHK subsidiary which is strategically situated in between CUHK campus and Hong Kong Science Park. The 3,800+ square foot facility is scheduled to be in operation in early 2021 and is expected to be fully compliant with the highly stringent international PIC/S standards shortly after opening.

###

For media enquiries, please contact pr@hkstp.org. Explore our latest news in the PRESS ROOM.

Contact Us

For general enquiry, or questions about HKSTP’s services and support, please enter your email address and query here.